Blocking the TSH receptor with K1-70™ in a patient with follicular thyroid cancer, Graves' disease and Graves' ophthalmopathy

Thyroid ◽  
2021 ◽  
Author(s):  
Mabel Ryder ◽  
Mark Wentworth ◽  
Alicia Algeciras-Schimnich ◽  
John C Morris ◽  
James Garrity ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Tsh Receptor ◽  
Graves Disease ◽  
Follicular Thyroid Cancer ◽  
Graves Ophthalmopathy

scholarly journals When Graves’ disease resists to surgery: A rare case of an association with follicular thyroid cancer in struma ovarii

2019 ◽  
Vol 80 (5-6) ◽  
pp. 329-331
Author(s):  
Carine Richa ◽  
Pauline Quilhot ◽  
Catherine Uzan ◽  
Camille Buffet ◽  
Charlotte Lussey-Lepoutre
Keyword(s):  
Thyroid Cancer ◽  
Rare Case ◽  
Graves Disease ◽  
Struma Ovarii ◽  
Follicular Thyroid Cancer

scholarly journals Influence of the TSH Receptor Gene on Susceptibility to Graves' Disease and Graves' Ophthalmopathy

Thyroid ◽  
2008 ◽  
Vol 18 (11) ◽  
pp. 1201-1206 ◽  
Author(s):  
Xiaoming Yin ◽  
Rauf Latif ◽  
Rebecca Bahn ◽  
Yaron Tomer ◽  
Terry F. Davies
Keyword(s):  
Receptor Gene ◽  
Tsh Receptor ◽  
Graves Disease ◽  
Graves Ophthalmopathy

Clinical Significance of Coexistence of Hashimoto Thyroiditis and Graves’ Disease with Differentiated and Medullary Thyroid Cancer

2021 ◽  
Author(s):  
Andreas Machens ◽  
Kerstin Lorenz ◽  
Frank Weber ◽  
Henning Dralle
Keyword(s):  
Thyroid Cancer ◽  
Medullary Thyroid Cancer ◽  
Hashimoto Thyroiditis ◽  
Graves Disease ◽  
Papillary Thyroid ◽  
Follicular Thyroid Cancer ◽  
Medullary Thyroid ◽  
Chronic Autoimmune Thyroiditis ◽  
Clinicopathological Study ◽  
Tumor Types

AbstractThe association of Hashimoto thyroiditis and Graves’ disease with papillary, follicular, and medullary thyroid cancer has not been comprehensively investigated until now. This comparative clinicopathological study of consecutive patients thyroidectomized at a surgical referral center aimed to explore interdependencies between chronic autoimmune thyroiditis and thyroid cancer. Altogether, there were 852 (58.4%) patients with papillary thyroid cancer, 181 (12.4%) patients with follicular thyroid cancer, and 426 (29.2%) patients with sporadic medullary thyroid cancer, of whom 75 (5.1%) patients also had Hashimoto thyroiditis and 40 (2.7%) patients also had Graves’ disease. Patients with papillary (medians of 42 vs. 48 years; P =0.008) and follicular (medians of 33 vs. 63 years; P=0.022) thyroid cancer, unlike patients with medullary thyroid cancer (medians of 57.5 vs. 57 years; P=0.989), were younger at thyroidectomy when they had Hashimoto thyroiditis concomitantly. No such associations were seen with Graves’ disease. Primary thyroid cancers tended to be more localized in conjunction with Hashimoto thyroiditis, and less so with Graves’ disease, although patterns were not consistent across tumor types. In conclusion, Hashimoto thyroiditis, but not Graves’ disease, may be associated with differentiated (papillary and follicular) thyroid cancer but not with medullary thyroid cancer.

scholarly journals Intermethod Variability in TSH-Receptor Antibody Measurement: Implication for the Diagnosis of Graves Disease and for the Follow-Up of Graves Ophthalmopathy

2009 ◽  
Vol 55 (1) ◽  
pp. 183-186 ◽  
Author(s):  
Catherine Massart ◽  
Rémy Sapin ◽  
Jacqueline Gibassier ◽  
Arnaud Agin ◽  
Michèle d'Herbomez
Keyword(s):  
Clinical Performance ◽  
Tsh Receptor ◽  
Graves Disease ◽  
Third Generation ◽  
Reference Standard ◽  
Receptor Antibody ◽  
Graves Ophthalmopathy ◽  
Specificity And Sensitivity ◽  
Recombinant Tsh

Abstract Background: We compared the analytical and clinical performance of 3 porcine thyroid receptor antibody (TRAb) methods (1 second- and 2 new third-generation systems) with the conventional TRAb assay based on the human recombinant TSH receptor (hTRAK). Patients and Methods: We obtained sera from 86 patients with untreated Graves disease (GD) and 71 healthy controls. We measured TRAb concentrations by radioreceptor assay using the hTRAK (Brahms) or the porcine TSH receptor (pRRA) from Beckman-Coulter, by electrochemiluminescence immunoassay (ECLIA) with the Elecsys/Cobas (Roche), and by ELISA using the Medizym TRAb clone (Medipan). Results: Between-run assay imprecision was ≤10% and ≤7.6% for hTRAK and ECLIA, but reached 14% and 14.9% for ELISA and pRRA, respectively. Maximal specificity and sensitivity close to 100% were obtained for hTRAK, ECLIA, and ELISA. pRRA failed to detect positive TRAbs in 5 GD patients. Although calibrated against the same reference standard 90/672, the assays displayed a high intermethod variability. The results were significantly higher by ECLIA and lower by ELISA and pRRA compared with hTRAK. Patients with ophthalmopathy had higher TRAb results by ELISA and pRRA than those without eye disease. Conclusions: Second- and third-generation TRAb assays had similar diagnostic sensitivities in the diagnostic evaluation of GD. Despite the use of the same reference standard for calibration, high intermethod variability in TRAb assay results was seen in untreated GD patients. Assay harmonization is necessary for correct interpretation in the follow-up of Graves ophthalmopathy.

Abstract #1070 An Unusual Case of Metastatic Follicular Thyroid Cancer 40 Years After Initial Diagnosis

2018 ◽  
Vol 24 ◽  
pp. 255
Author(s):  
Lakshmi Menon ◽  
Yuanjie Mao ◽  
Sanaz Abedzadeh-Anaraki ◽  
Spyridoula Maraka
Keyword(s):  
Thyroid Cancer ◽  
Unusual Case ◽  
Initial Diagnosis ◽  
Follicular Thyroid Cancer

TSH-Receptor autoantibodies help to predict severity and outcome of Graves' ophthalmopathy

2005 ◽  
Vol 113 (S 1) ◽  
Author(s):  
A Eckstein ◽  
M Plicht ◽  
H Lax ◽  
B Quadbeck ◽  
K Mann ◽  
...  
Keyword(s):  
Tsh Receptor ◽  
Graves Ophthalmopathy

Relevance of TSH-Receptor stimulating and blocking autoantibody measurement for the prediction of relapse in Graves' disease

2005 ◽  
Vol 113 (S 1) ◽  
Author(s):  
M Schott ◽  
WB Minich ◽  
C Papewalis ◽  
J Seissler ◽  
WA Scherbaum ◽  
...  
Keyword(s):  
Tsh Receptor ◽  
Graves Disease ◽  
Prediction Of Relapse

Anti-thyrotrophin receptor antibodies in Graves' disease as demonstrated directly by immunoprecipitation assay

1983 ◽  
Vol 102 (1) ◽  
pp. 49-56 ◽  
Author(s):  
Tjerk W. A de Bruin ◽  
Daan van der Heide ◽  
Maria C. Krol
Keyword(s):  
Binding Site ◽  
Tsh Receptor ◽  
Graves Disease ◽  
Immunoprecipitation Assay ◽  
Receptor Complexes ◽  
Auto Antibody ◽  
Receptor Antibodies ◽  
Normal Controls

Abstract. An immunoprecipitation assay was developed to determine the presence of antibodies against human TSH1 receptors. With this assay we were able to demonstrate that in comparison with sera from normal controls, 24 out of 30 (80%) sera from patients with untreated Graves' disease could immunoprecipitate more [125I]TSH-TSH receptor complexes. In 9 assays, an average of 14.1 ± 3.7% (sd) of the [125I]TSH-TSH receptor complexes was immunoprecipitated by the 30 Graves' sera vs 9.8 ± 3.0% by the normal pool serum (n = 23) (P < 0.001) and 7.7 ± 2.8% by the 22 normal sera (P < 0.001). One serum of the 24 positive Graves' sera was studied in detail. The results suggest that this serum contained an anti-TSH receptor auto-antibody directed towards a different determinant on the TSH receptor than the TSH binding site.

Sign in / Sign up

Export Citation Format

Share Document